E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute respiratory distress syndrome |
|
E.1.1.1 | Medical condition in easily understood language |
In patients mechanically ventiltated in ICU for reasons that are unclear, their lungs fail and fill with water making breathing difficult this is termed the Acute Respiratory Distress Syndrome (ARDS) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of this study is to test the hypothesis that aspirin will be effective in the treatment of patients with acute respiratory distress syndrome (ARDS)
The trial objective is to undertaken a randomised double blind placebo controlled (i.e. dummy medication) clinical trial to study whether aspirin improves important surrogate markers of clinical outcome and is safe in adult patients with ARDS in intensive care. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to investigate if aspirin has effect on important surrogate markers of biologic outcomes in ARDS. This will help in the future design of other clinical trials with either with aspirin or with other potential therapeutic agents |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients receiving invasive mechanical ventilation 2. ARDS as defined by the Berlin definition a) Onset within 1 week of identified insult b) Within the same 24 hour time period i. Hypoxic respiratory failure (PaO2/ FiO2 ratio ≤ 40kPa on PEEP ≥ 5 cmH20) ii. Bilateral infiltrates on chest X-ray consistent with pulmonary oedema not explained by another pulmonary pathology iii. No evidence of heart failure or volume overload
|
|
E.4 | Principal exclusion criteria |
1. More than 72 hours from the onset of ARDS 2. Age < 16 years 3. Patient is known to be pregnant 4. Participation in a clinical trial of an investigational medicinal product within 30 days 5. Current treatment with aspirin or within the past 4 weeks 6. Platelet count < 50 x 109/l 7. Haemophilia or other haemorrhagic disorder or concurrent therapeutic anticoagulant therapy 8. History of aspirin sensitive asthma or nasal polyps associated with asthma 9. Active peptic ulcer disease or endoscopically proven history of peptic ulceration 10. Traumatic brain injury 11. Severe chronic liver disease with Child-Pugh score > 12 12. Active or recent bleeding (in previous 3 months) 13. Known hypersensitivity or previous adverse reaction to aspirin 14. Physician decision that aspirin is required for proven indication 15. Contraindication to enteral drug administration, e.g. patients with mechanical bowel obstruction. 16. Treatment withdrawal imminent within 24 hours 17. Consent declined.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of this clinical study is to evaluate the efficacy of aspirin to improve oxygenation index (OI) at day 7.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
We have chosen day 7 as we expect this time interval will minimise the competing effects of death and extubation, while allowing a sufficient time interval for a biological effect to occur.
|
|
E.5.2 | Secondary end point(s) |
1) OI at days 4 and 14 2) Physiological indices of ARDS, as measured by respiratory compliance (Crs) and P/F ratio on days 4, 7 and 14 3) Organ failure as measured by the change in sequential organ failure assessment (SOFA) score from baseline to day 4, 7 and 14 4) Safety and tolerability as assessed by the occurrence of suspected unexpected serious adverse reactions (SUSAR).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end when 60 patients have been recruited and completed 90-day follow-up, samples analysed and database locked.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 28 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 28 |